Cargando…
The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China
BACKGROUND: KCNH2 (hERG) potassium channels have an integral role in regulating the excitability of smooth muscle cells. Some pathways driven by angiotensin II, nitric oxide and adrenergic receptors blocker are involved in modulating the properties of KCNH2 potassium channels. And these pathways are...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632552/ https://www.ncbi.nlm.nih.gov/pubmed/23613831 http://dx.doi.org/10.1371/journal.pone.0061317 |
_version_ | 1782266877703094272 |
---|---|
author | He, Fazhong Luo, Jianquan Luo, Zhiying Fan, Lan He, Yijing Zhu, Dingliang Gao, Jinping Deng, Sheng Wang, Yan Qian, Yuesheng Zhou, Honghao Chen, Xiaoping Zhang, Wei |
author_facet | He, Fazhong Luo, Jianquan Luo, Zhiying Fan, Lan He, Yijing Zhu, Dingliang Gao, Jinping Deng, Sheng Wang, Yan Qian, Yuesheng Zhou, Honghao Chen, Xiaoping Zhang, Wei |
author_sort | He, Fazhong |
collection | PubMed |
description | BACKGROUND: KCNH2 (hERG) potassium channels have an integral role in regulating the excitability of smooth muscle cells. Some pathways driven by angiotensin II, nitric oxide and adrenergic receptors blocker are involved in modulating the properties of KCNH2 potassium channels. And these pathways are closely related to blood pressure regulation. Therefore, we hypothesized that KCNH2 genetic polymorphisms may affect blood pressure response to the antihypertensive drug therapies. MATERIALS AND METHODS: To evaluate the interactions between KCNH2 genetic polymorphisms and individual blood pressure response to antihypertensive drugs, 370 subjects with essential hypertension (EH) were studied. In evaluating the interactions between KCNH2 genetic polymorphisms and drug response to blood pressure, multivariable ANOVA analysis followed by Bonferroni correction were carried out. RESULTS: There were statistically significant interactions between KCNH2 (1956, C>T) polymorphism and DBP change (P = 0.010), MAP change (P = 0.014) on azelnidipine or nitrendipine therapy patients at the end of 6 weeks. We found that the KCNH2 (1956,C>T) polymorphism was associated with the hypotensive effects of α,β-ADR blockers of DBP change at the end of 4 and 6 weeks' treatment in an age- and gender-dependent manner (P = 0.007 and 0.019, respectively). Similar results were also observed for changes in MAP at the end of 4 and 6 weeks (P-values were 0.035 and 0.078, respectively). While patients who received imidapril, candesartan and irbesartan therapy, no significant difference in drug response among KCNH2(1956,C>T) genotype was observed. CONCLUSION: We have reported for the first time that KCNH2 (1956, C>T) polymorphism is associated with efficacy of antihypertensive drugs CCBs and ADR blockers, and may serve as a novel biomarker for individualized therapy for certain antihypertensive drugs. |
format | Online Article Text |
id | pubmed-3632552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36325522013-04-23 The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China He, Fazhong Luo, Jianquan Luo, Zhiying Fan, Lan He, Yijing Zhu, Dingliang Gao, Jinping Deng, Sheng Wang, Yan Qian, Yuesheng Zhou, Honghao Chen, Xiaoping Zhang, Wei PLoS One Research Article BACKGROUND: KCNH2 (hERG) potassium channels have an integral role in regulating the excitability of smooth muscle cells. Some pathways driven by angiotensin II, nitric oxide and adrenergic receptors blocker are involved in modulating the properties of KCNH2 potassium channels. And these pathways are closely related to blood pressure regulation. Therefore, we hypothesized that KCNH2 genetic polymorphisms may affect blood pressure response to the antihypertensive drug therapies. MATERIALS AND METHODS: To evaluate the interactions between KCNH2 genetic polymorphisms and individual blood pressure response to antihypertensive drugs, 370 subjects with essential hypertension (EH) were studied. In evaluating the interactions between KCNH2 genetic polymorphisms and drug response to blood pressure, multivariable ANOVA analysis followed by Bonferroni correction were carried out. RESULTS: There were statistically significant interactions between KCNH2 (1956, C>T) polymorphism and DBP change (P = 0.010), MAP change (P = 0.014) on azelnidipine or nitrendipine therapy patients at the end of 6 weeks. We found that the KCNH2 (1956,C>T) polymorphism was associated with the hypotensive effects of α,β-ADR blockers of DBP change at the end of 4 and 6 weeks' treatment in an age- and gender-dependent manner (P = 0.007 and 0.019, respectively). Similar results were also observed for changes in MAP at the end of 4 and 6 weeks (P-values were 0.035 and 0.078, respectively). While patients who received imidapril, candesartan and irbesartan therapy, no significant difference in drug response among KCNH2(1956,C>T) genotype was observed. CONCLUSION: We have reported for the first time that KCNH2 (1956, C>T) polymorphism is associated with efficacy of antihypertensive drugs CCBs and ADR blockers, and may serve as a novel biomarker for individualized therapy for certain antihypertensive drugs. Public Library of Science 2013-04-22 /pmc/articles/PMC3632552/ /pubmed/23613831 http://dx.doi.org/10.1371/journal.pone.0061317 Text en © 2013 He et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article He, Fazhong Luo, Jianquan Luo, Zhiying Fan, Lan He, Yijing Zhu, Dingliang Gao, Jinping Deng, Sheng Wang, Yan Qian, Yuesheng Zhou, Honghao Chen, Xiaoping Zhang, Wei The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title | The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title_full | The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title_fullStr | The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title_full_unstemmed | The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title_short | The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China |
title_sort | kcnh2 genetic polymorphism (1956, c>t) is a novel biomarker that is associated with ccb and α,β-adr blocker response in eh patients in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632552/ https://www.ncbi.nlm.nih.gov/pubmed/23613831 http://dx.doi.org/10.1371/journal.pone.0061317 |
work_keys_str_mv | AT hefazhong thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT luojianquan thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT luozhiying thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT fanlan thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT heyijing thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhudingliang thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT gaojinping thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT dengsheng thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT wangyan thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT qianyuesheng thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhouhonghao thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT chenxiaoping thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhangwei thekcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT hefazhong kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT luojianquan kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT luozhiying kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT fanlan kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT heyijing kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhudingliang kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT gaojinping kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT dengsheng kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT wangyan kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT qianyuesheng kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhouhonghao kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT chenxiaoping kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina AT zhangwei kcnh2geneticpolymorphism1956ctisanovelbiomarkerthatisassociatedwithccbandabadrblockerresponseinehpatientsinchina |